Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319

Fibroblast growth factor 21 is a novel hormonal regulator with the potential to treat a broad variety of metabolic abnormalities, such as type 2 diabetes, obesity, hepatic steatosis, and cardiovascular disease. Human recombinant wild type FGF21 (FGF21) has been shown to ameliorate metabolic disorders in rodents and non-human primates. However, development of FGF21 as a drug is challenging and requires re-engineering of its amino acid sequence to improve protein expression and formulation stability. Here we report the design and characterization of a novel FGF21 variant, LY2405319. To enable the development of a potential drug product with a once-daily dosing profile, in a preserved, multi-use formulation, an additional disulfide bond was introduced in FGF21 through Leu118Cys and Ala134Cys mutations. FGF21 was further optimized by deleting the four N-terminal amino acids, His-Pro-Ile-Pro (HPIP), which was subject to proteolytic cleavage. In addition, to eliminate an O-linked glycosylation site in yeast a Ser167Ala mutation was introduced, thus allowing large-scale, homogenous protein production in Pichia pastoris. Altogether re-engineering of FGF21 led to significant improvements in its biopharmaceutical properties. The impact of these changes was assessed in a panel of in vitro and in vivo assays, which confirmed that biological properties of LY2405319 were essentially identical to FGF21. Specifically, subcutaneous administration of LY2405319 in ob/ob and diet-induced obese (DIO) mice over 7–14 days resulted in a 25–50% lowering of plasma glucose coupled with a 10–30% reduction in body weight. Thus, LY2405319 exhibited all the biopharmaceutical and biological properties required for initiation of a clinical program designed to test the hypothesis that administration of exogenous FGF21 would result in effects on disease-related metabolic parameters in humans.

[1]  Jason K. Kim,et al.  Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice , 2009, Diabetes.

[2]  Yun-Fei Chen,et al.  The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. , 2007, Endocrinology.

[3]  M. Konishi,et al.  Identification of a novel FGF, FGF-21, preferentially expressed in the liver. , 2000, Biochimica et biophysica acta.

[4]  K. Okawa,et al.  Klotho converts canonical FGF receptor into a specific receptor for FGF23 , 2006, Nature.

[5]  P. Pfluger,et al.  Restoration of leptin responsiveness in diet‐induced obese mice using an optimized leptin analog in combination with exendin‐4 or FGF21 , 2012, Journal of peptide science : an official publication of the European Peptide Society.

[6]  K. Rosenblatt,et al.  βKlotho is required for metabolic activity of fibroblast growth factor 21 , 2007, Proceedings of the National Academy of Sciences.

[7]  Wayne R. Gombotz,et al.  Interleukin-1 Receptor (IL-1R) Liquid Formulation Development Using Differential Scanning Calorimetry , 1998, Pharmaceutical Research.

[8]  T. Patapoff,et al.  The Effect of Benzyl Alcohol on Recombinant Human Interferon-γ , 1997, Pharmaceutical Research.

[9]  J. Cregg,et al.  Applications of yeast in biotechnology: protein production and genetic analysis. , 1999, Current opinion in biotechnology.

[10]  Dan Yu,et al.  [Optimization and characterization of a novel FGF21 mutant]. , 2012, Yao xue xue bao = Acta pharmaceutica Sinica.

[11]  Margaret S. Wu,et al.  FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents , 2012, Diabetes.

[12]  Katherine A. Winters,et al.  Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. , 2012, Endocrinology.

[13]  J. D. Dunbar,et al.  Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo , 2012, PloS one.

[14]  A. Kharitonenkov,et al.  FGF21 reloaded: challenges of a rapidly growing field , 2011, Trends in Endocrinology & Metabolism.

[15]  J. Xu,et al.  FGF21 N‐ and C‐termini play different roles in receptor interaction and activation , 2009, FEBS letters.

[16]  Dale E Tronrud,et al.  Lessons from the lysozyme of phage T4 , 2010, Protein science : a publication of the Protein Society.

[17]  N. Itoh Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease , 2010, Cell and Tissue Research.

[18]  A. Xu,et al.  Growth Hormone Induces Hepatic Production of Fibroblast Growth Factor 21 through a Mechanism Dependent on Lipolysis in Adipocytes* , 2011, The Journal of Biological Chemistry.

[19]  J. Gromada,et al.  FGF-21 as a novel metabolic regulator. , 2005, The Journal of clinical investigation.

[20]  Wei Wang,et al.  Immunogenicity of protein aggregates--concerns and realities. , 2012, International journal of pharmaceutics.

[21]  D. Driver,et al.  Different roles of N‐ and C‐ termini in the functional activity of FGF21 , 2009, Journal of cellular physiology.

[22]  D. Moller Metabolic disease drug discovery- "hitting the target" is easier said than done. , 2012, Cell metabolism.

[23]  D. Brems,et al.  Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. , 2006, Journal of pharmaceutical sciences.

[24]  J. D. Dunbar,et al.  FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho , 2008, Journal of cellular physiology.

[25]  F. Mehrbod,et al.  Molecular determinants of FGF‐21 activity—synergy and cross‐talk with PPARγ signaling , 2007, Journal of cellular physiology.

[26]  D. Moller,et al.  Fibroblast growth factor 21 corrects obesity in mice. , 2008, Endocrinology.

[27]  D. Hallén,et al.  Solvent Effects on the Solubility and Physical Stability of Human Insulin-Like Growth Factor I , 1997, Pharmaceutical Research.

[28]  K D Wittrup,et al.  Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. , 1999, Journal of molecular biology.

[29]  J. Cregg,et al.  Introduction to Pichia pastoris. , 1998, Methods in molecular biology.

[30]  Masashi Suzuki,et al.  betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. , 2008, Molecular endocrinology.

[31]  Chung C. Hsu,et al.  Aggregation of recombinant human growth hormone induced by phenolic compounds , 1996 .

[32]  H. Waterham,et al.  Peroxisomal Targeting, Import, and Assembly of Alcohol Oxidase in Pichia pastoris , 1997, The Journal of cell biology.

[33]  R. Gimeno,et al.  The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. , 2013, Molecular metabolism.

[34]  F. Schmidt,et al.  Recombinant expression systems in the pharmaceutical industry , 2004, Applied Microbiology and Biotechnology.

[35]  A. Adams,et al.  FGF21 Requires βklotho to Act In Vivo , 2012, PloS one.